KSQ Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 103

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

KSQ General Information

Description

Developer of transformative medicines designed to systematically pinpoint the optimal nodal targets of disease with precision. The company's industrialized functional genomics engine utilizes a suite of tools that identify novel pathways and targets involved in oncology and immuno-oncology, enabling doctors to uncover novel drug targets, and mechanisms for drug efficacy and identify transformative single-agent and combination therapies to benefit patients.

Contact Information

Website
www.ksqtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4 Maguire Road
  • Lexington, MA 02421
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • 4 Maguire Road
  • Lexington, MA 02421
  • United States
+1 (617)

KSQ Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KSQ Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 01-Jul-2026 Completed Clinical Trials - Phase 1
8. Secondary Transaction - Private Completed Clinical Trials - Phase 1
7. Mezzanine 31-Mar-2025 Completed Clinical Trials - Phase 1
6. Mezzanine 26-Apr-2022 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series D) 23-Dec-2021 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 28-Sep-2018 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 02-Oct-2017 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 16-Mar-2017 $10M $25.5M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 20-Oct-2015 $15.5M $15.5M Completed Startup
To view KSQ’s complete valuation and funding history, request access »

KSQ Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 22,566,371 $0.000100 $2.26 $2.26 1x $2.26 19.56%
Series A 25,560,000 $0.000100 $1 $1 1x $1 22.15%
To view KSQ’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

KSQ Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of transformative medicines designed to systematically pinpoint the optimal nodal targets of disease with prec
Biotechnology
Lexington, MA
103 As of 2022

Rockville, MD
 

Bangalore, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

KSQ Competitors (38)

One of KSQ’s 38 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
Strand (Biotechnology) Formerly VC-backed Bangalore, India
Partek Corporate Backed or Acquired Chesterfield, MO
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 5 of 38 competitors. Get the full list »

KSQ Patents

KSQ Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026107320-A1 Gene-regulating compositions and methods for improved immunotherapy Pending 15-Nov-2024
WO-2025106513-A1 Methods for producing edited tumor infiltrating lymphocytes Inactive 13-Nov-2023
WO-2025106513-A8 Methods for producing edited tumor infiltrating lymphocytes Inactive 13-Nov-2023
AU-2023347293-A1 Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors Pending 23-Sep-2022
EP-4590297-A2 Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors Pending 23-Sep-2022 A61K31/519
To view KSQ’s complete patent history, request access »

KSQ Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KSQ Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
LG Technology Ventures Corporate Venture Capital Minority
UCSF Innovation Ventures Venture Capital Minority
To view KSQ’s complete investors history, request access »

KSQ FAQs

  • When was KSQ founded?

    KSQ was founded in 2015.

  • Where is KSQ headquartered?

    KSQ is headquartered in Lexington, MA.

  • What is the size of KSQ?

    KSQ has 103 total employees.

  • What industry is KSQ in?

    KSQ’s primary industry is Biotechnology.

  • Is KSQ a private or public company?

    KSQ is a Private company.

  • What is KSQ’s current revenue?

    The current revenue for KSQ is .

  • How much funding has KSQ raised over time?

    KSQ has raised $324M.

  • Who are KSQ’s investors?

    LG Technology Ventures and UCSF Innovation Ventures have invested in KSQ.

  • Who are KSQ’s competitors?

    Regenxbio, Strand (Biotechnology), Partek, Adaptimmune Therapeutics, and Genetix Biotherapeutics are some of the 38 competitors of KSQ.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process